Atherosclerosis Market
Atherosclerosis Market Forecasts to 2030 - Global Analysis By Type (Plaque Growth, Plaque Rupture, Endothelial Damage and Immune Response, Fatty Streak and Other Stages), Treatment, Route of Administration, Distribution Channel, Diagnosis, End User and By Geography
|
Years Covered |
2021-2030 |
|
CAGR (2023 - 2030) |
4.24% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Atherosclerosis Market is growing at a CAGR of 4.24% during the forecast period. Atherosclerosis is the term used to describe the gradual hardening and construction of your arteries brought on by cholesterol plaques lining them. The use of medications to treat high blood pressure and high cholesterol will reduce, if not stop, atherosclerosis. They lessen your risk of experiencing a heart attack or stroke. Bypass surgery includes utilizing a vascular from another region of body or a synthetic tube to redirect blood around a blocked or constricted artery. To dissolve a blood clot, thrombolytic treatment involves injecting a drug into the affected artery. Atherectomy is the process of removing plaque from your arteries using a catheter with a cutting edge at one end.
According to the European Heart Network, cardiovascular disease affects 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union.
Market Dynamics:
Driver:
Increasing prevalence of cardiovascular diseases
It is predicted that the market would develop faster due to the increased frequency of cardiovascular disorders worldwide. Sedentary lifestyles are to blame for the highest incidence of cardiovascular disease in developed nations. Additionally, a rise in the elderly population and a sedentary lifestyle that results in a high frequency of cardiovascular illnesses and growing awareness of available treatments is predicted to boost the market under study.
Restraint:
Side effects associated with atherosclerosis
The risk of cardiovascular events like heart attacks and strokes is increased by atherosclerosis. These occurrences may result in death or serious disability. Peripheral artery disease may be brought on by atherosclerosis in the arteries of the extremities, particularly the legs. This may result in discomfort, numbness, and trouble walking. This can put more stress on the cardiovascular system by making arteries less elastic and raising blood pressure. Growth of the market is anticipated to be hampered by the adverse effects of atherosclerosis and the low effectiveness.
Opportunity:
Increasing infrastructure spending for healthcare
The increase in healthcare spending, which aids in enhancing its infrastructure, is the element driving the market's growth rate. By boosting funds, a number of government agencies seek to enhance the healthcare infrastructure. Rising awareness-raising efforts by both governmental and private organizations, an increase in disposable income, and the high incidence of high blood pressure are other key elements that are projected to boost the market's growth rate throughout the course of the forecast year.
Threat:
High cost of treatment
The continuing treatment of atherosclerosis using prescription drugs, diagnostic exams, and surgical procedures is necessary. These medical treatments can be quite expensive for both individuals and families. Furthermore, the costs of hospitalization, surgery, and rehabilitation are frequently significant when addressing side effects including heart attacks and strokes. To treat their illness and lower the risk of complications, many people with atherosclerosis need medication. The market expansion is being constrained by the cost and potential duration of use of these treatments.
Covid-19 Impact:
The COVID-19 pandemic had a detrimental effect on the market for atherosclerosis medications since it delayed financing from several firms involved in research and development as well as investments in innovative atherosclerosis therapies that target the disease. Additionally, the pandemic had a detrimental effect on the atherosclerosis clinical studies that were in progress, which hampered the expansion of the worldwide market for atherosclerosis medications as a result of the delayed clinical trials.
The oral segment is expected to be the largest during the forecast period
The oral segment is expected to be the largest during the forecast period. This is due to a rise in knowledge about routine cholesterol testing and therapy as well as sedentary lifestyles that have been linked to the onset of other ailments, including diabetes. Additionally, the mucosal permeability, drug solubility, and environmental stability in the gastrointestinal tract are benefits of oral medications. As a result, their demand is larger, which helps the market share growth of medications for atherosclerosis.
The retail pharmacy segment is expected to have the highest CAGR during the forecast period
The retail pharmacy segment is expected to have the highest CAGR during the forecast period. This is linked to a growth in the desire for buying medications from drug shops and retail pharmacies owing to the availability of cheap and reasonably priced medications as well as the simplicity of obtaining cardiovascular medications in these pharmacies. Additionally, customers who visit retail pharmacies and drug shops to buy atherosclerosis meds benefit from the ability to learn all there is to know about the prescriptions, which serves to fuel the segment's expansion.
Region with largest share:
North America is projected to hold the largest market share during the forecast period due to increase in government and private sector efforts to promote healthy lifestyles. The market is anticipated to increase as a result of the well-established healthcare infrastructure, strong buying power, and rising acceptance of atherosclerosis treatment products. In addition, rising cardiovascular disease incidence in the area and increased public awareness of disease prevention are driving up demand for atherosclerosis medications and propelling the market's expansion.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period. This is due to the presence of pharmaceutical businesses in the area as well as the increase in the purchasing power of populous nations. The market is expanding as a result of the growing number of elderly people who are suffering from different cardiovascular ailments. Additionally, because of the huge population base, unmet medical demands, and rise in disposable income, it has a great growth potential. Additionally, a profitable market is created by the expansion of medical tourism and growing healthcare infrastructure.
Key players in the market
Some of the key players in Atherosclerosis Market include Boehringer Ingelheim International GmbH., Bayer AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd. , Philips Healthcare, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Sanofi, Allergan, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc. and Mylan N.V.
Key Developments:
In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development.
In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.
In December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio, the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol with two doses a year, after an initial dose and one at three months.
Stages Covered:
• Plaque Growth
• Plaque Rupture
• Endothelial Damage and Immune Response
• Fatty Streak
• Other Stages
Treatments Covered:
• Medication
• Surgery
• Other Treatments
Route of Administrations Covered:
• Parenteral
• Oral
Distribution Channels Covered:
• Retail Pharmacy
• Online Pharmacy
Diagnosis Covered:
• Doppler Ultrasound
• Blood Tests
• Ankle-brachial Index (ABI)
• Echocardiogram
• Electrocardiogram (ECG)
• Other Diagnosis
End Users Covered:
• Specialty Clinics
• Homecare
• Hospitals
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Atherosclerosis Market, By Stage
5.1 Introduction
5.2 Plaque Growth
5.3 Plaque Rupture
5.4 Endothelial Damage and Immune Response
5.5 Fatty Streak
5.6 Other Stages
6 Global Atherosclerosis Market, By Treatment
6.1 Introduction
6.2 Medication
6.2.1 Beta Blockers
6.2.2 Angiotensin-Converting Enzyme (Ace) Inhibitors
6.2.3 Calcium Channel Blockers
6.2.4 Anti-Platelet Drugs
6.2.5 Cholesterol Lowering Medications
6.3 Surgery
6.3.1 Fibrinolytic therapy
6.3.2 Endarterectomy
6.3.3 Coronary artery bypass surgery
6.3.4 Angioplasty
6.4 Other Treatments
7 Global Atherosclerosis Market, By Route of Administration
7.1 Introduction
7.2 Parenteral
7.3 Oral
8 Global Atherosclerosis Market, By Distribution Channel
8.1 Introduction
8.2 Retail Pharmacy
8.3 Online Pharmacy
9 Global Atherosclerosis Market, By Diagnosis
9.1 Introduction
9.2 Doppler Ultrasound
9.3 Blood Tests
9.4 Ankle-brachial Index (ABI)
9.5 Echocardiogram
9.6 Electrocardiogram (ECG)
9.7 Other Diagnosis
10 Global Atherosclerosis Market, By End User
10.1 Introduction
10.2 Specialty Clinics
10.3 Homecare
10.4 Hospitals
10.5 Other End Users
11 Global Atherosclerosis Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Boehringer Ingelheim International GmbH.
13.2 Bayer AG
13.3 Teva Pharmaceutical Industries Ltd.
13.4 Pfizer Inc.
13.5 Lupin
13.6 GlaxoSmithKline plc
13.7 Dr. Reddy's Laboratories Ltd.
13.8 Philips Healthcare
13.9 F. Hoffmann-La Roche Ltd.
13.10 Novartis AG
13.11 Bristol-Myers Squibb Company
13.12 Sanofi
13.13 Allergan
13.14 Eli Lilly and Company
13.15 AbbVie Inc.
13.16 Amgen Inc.
13.17 Gilead Sciences, Inc.
13.18 Hikma Pharmaceuticals PLC
13.19 Johnson & Johnson Private Limited
13.20 AstraZeneca
13.21 Merck & Co., Inc.
13.22 Mylan N.V.
List of Tables
1 Global Atherosclerosis Market Outlook, By Region (2021-2030) ($MN)
2 Global Atherosclerosis Market Outlook, By Stage (2021-2030) ($MN)
3 Global Atherosclerosis Market Outlook, By Plaque Growth (2021-2030) ($MN)
4 Global Atherosclerosis Market Outlook, By Plaque Rupture (2021-2030) ($MN)
5 Global Atherosclerosis Market Outlook, By Endothelial Damage and Immune Response (2021-2030) ($MN)
6 Global Atherosclerosis Market Outlook, By Fatty Streak (2021-2030) ($MN)
7 Global Atherosclerosis Market Outlook, By Other Stages (2021-2030) ($MN)
8 Global Atherosclerosis Market Outlook, By Treatment (2021-2030) ($MN)
9 Global Atherosclerosis Market Outlook, By Medication (2021-2030) ($MN)
10 Global Atherosclerosis Market Outlook, By Beta Blockers (2021-2030) ($MN)
11 Global Atherosclerosis Market Outlook, By Angiotensin-Converting Enzyme (Ace) Inhibitors (2021-2030) ($MN)
12 Global Atherosclerosis Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
13 Global Atherosclerosis Market Outlook, By Anti-Platelet Drugs (2021-2030) ($MN)
14 Global Atherosclerosis Market Outlook, By Cholesterol Lowering Medications (2021-2030) ($MN)
15 Global Atherosclerosis Market Outlook, By Surgery (2021-2030) ($MN)
16 Global Atherosclerosis Market Outlook, By Fibrinolytic therapy (2021-2030) ($MN)
17 Global Atherosclerosis Market Outlook, By Endarterectomy (2021-2030) ($MN)
18 Global Atherosclerosis Market Outlook, By Coronary artery bypass surgery (2021-2030) ($MN)
19 Global Atherosclerosis Market Outlook, By Angioplasty (2021-2030) ($MN)
20 Global Atherosclerosis Market Outlook, By Other Treatments (2021-2030) ($MN)
21 Global Atherosclerosis Market Outlook, By Route of Administration (2021-2030) ($MN)
22 Global Atherosclerosis Market Outlook, By Parenteral (2021-2030) ($MN)
23 Global Atherosclerosis Market Outlook, By Oral (2021-2030) ($MN)
24 Global Atherosclerosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
25 Global Atherosclerosis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
26 Global Atherosclerosis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
27 Global Atherosclerosis Market Outlook, By Diagnosis (2021-2030) ($MN)
28 Global Atherosclerosis Market Outlook, By Doppler Ultrasound (2021-2030) ($MN)
29 Global Atherosclerosis Market Outlook, By Blood Tests (2021-2030) ($MN)
30 Global Atherosclerosis Market Outlook, By Ankle-brachial Index (ABI) (2021-2030) ($MN)
31 Global Atherosclerosis Market Outlook, By Echocardiogram (2021-2030) ($MN)
32 Global Atherosclerosis Market Outlook, By Electrocardiogram (ECG) (2021-2030) ($MN)
33 Global Atherosclerosis Market Outlook, By Other Diagnosis (2021-2030) ($MN)
34 Global Atherosclerosis Market Outlook, By End User (2021-2030) ($MN)
35 Global Atherosclerosis Market Outlook, By Specialty Clinics (2021-2030) ($MN)
36 Global Atherosclerosis Market Outlook, By Homecare (2021-2030) ($MN)
37 Global Atherosclerosis Market Outlook, By Hospitals (2021-2030) ($MN)
38 Global Atherosclerosis Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
List of Figures
Figure 1 Global Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 2 North America Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 3 US Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 4 Canada Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 5 Mexico Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 6 Europe Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 7 Germany Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 8 UK Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 9 Italy Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 10 France Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 11 Spain Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 12 Rest of Europe Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 13 Asia Pacific Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 14 Japan Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 15 China Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 16 India Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 17 Australia Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 18 New Zealand Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 19 South Korea Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 20 Rest of Asia Pacific Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 21 South America Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 22 Argentina Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 23 Brazil Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 24 Chile Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 25 Rest of South America Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 26 Middle East & Africa Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 27 Saudi Arabia Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 28 UAE Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 29 Qatar Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 30 South Africa Atherosclerosis Market Outlook (2021-2030) ($MN)
Figure 31 Rest of Middle East & Africa Atherosclerosis Market Outlook (2021-2030) ($MN)
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
